Diagnosis

MASLD: Sharp Increases in Liver Disease Deaths by 2050

This decision analytical modeling study projected the long-term clinical burden of metabolic dysfunction-associated steatotic liver disease (MASLD) in the US adult population from 2020 to 2050 using an...

Jennifer Geremia,

MSPAS, PA-C
Physician Associate, Brigham and Women’s Hospital
and Teaching Hospital of Harvard Medical School

Non-invasive Tests Show Promise for Identifying High-Risk MASH

This multicenter cross-sectional study evaluated the diagnostic performance of non-invasive tests (NITs) in detecting metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis...

CURATED BY:
Chantil D. Jeffreys,
FNP, DNP, JD

Sequential NIT Screening for MASH Reduces Biopsies and Costs

This study evaluated the diagnostic performance of non-invasive tests (NITs) like the FibroScan-AST (FAST) score, LSM-VCTE, FIB-4, and NFS for...

CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Study Develops Noninvasive MASH Dx Score

A study aimed to develop a noninvasive tool to diagnose high-risk metabolic dysfunction-associated steatohepatitis (MASH) using proteomics-derived serum markers and...

CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Advancements in MASLD Diagnosis: Non-Invasive Tools

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NASH, is a growing health concern due to its association with...

CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Detecting Significant Fibrosis in Hispanic Patients With MASLD

A recent study evaluated the performance of noninvasive tests (NITs) for detecting significant fibrosis in Hispanic patients with metabolic dysfunction–associated...